Dr Samuel Sanchez PSC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$460,805	101
2024	Research	$386,831	82
2023	Research	$288,426	59
2022	Research	$247,211	33
2021	Research	$211,608	47
2020	Research	$142,970	35
2019	Research	$358,817	16

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $1,048,812 290 payments
Eli Lilly Export S.A. Puerto Rico Branch $940,925 40 payments
Eli Lilly and Company $106,431 42 payments
E.R. Squibb & Sons, L.L.C. $500 1 payment

Studies the money was for Research payments · program years 2019–2025

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the Rebuild Study $272,989 13 payments
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-To-Severe Plaque Psoriasis $128,671 4 payments
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $115,044 27 payments
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) $99,707 19 payments
Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $96,079 4 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Ly3375880 in Adult Subjects With Moderate-To-Severe Atopic Dermatitis: the Admire Study $91,986 3 payments
A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Ly3074828 in Patients With Moderate-To-Severe Plaque Psoriasis Oasis-3 $84,404 7 payments
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) $73,941 23 payments
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis $73,822 23 payments
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement $65,760 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.